Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma

Pembrolizumab has been available for the treatment of radical resectable urothelial carcinoma (UC) when it is exacerbated after chemotherapy since December 2017 in Japan. However, the efficacy of chemotherapy for cases progressing after pembrolizumab is unclear. The present study compared the outcom...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Mol Clin Oncol
Main Authors: Furubayashi, Nobuki, Hori, Yoshifumi, Morokuma, Futoshi, Tomoda, Toshihisa, Negishi, Takahito, Inoue, Tomohiro, Kumagai, Masatoshi, Kuroiwa, Kentaro, Tokuda, Noriaki, Nakamura, Motonobu
Formato: Artigo
Idioma:Inglês
Publicado: D.A. Spandidos 2021
Assuntos:
Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7976390/
https://ncbi.nlm.nih.gov/pubmed/33767860
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2021.2253
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares